Hotspot Therapeutics Inc. has identified diazepino-thieno-quinoxaline compounds acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of cancer, arthritis, asthma, psoriasis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis and inflammatory disorders.
Hotspot Therapeutics Inc. has identified mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.
HST-1021 is a novel mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) allosteric inhibitor identified using the Smart Allostery Platform, and is being developed for the potential treatment of tumors.
Hotspot Therapeutics Inc. has received FDA clearance of its IND application for HST-1011, the company's investigational small-molecule allosteric inhibitor of casitas B-lineage lymphoma-B (CBL-B), an E3 ubiquitin protein ligase critically involved in immune cell response.
Abbvie Inc. and Hotspot Therapeutics Inc. have entered into an exclusive worldwide collaboration and option to license agreement for Hotspot's discovery-stage interferon regulatory factor 5 (IRF5) program for the treatment of autoimmune diseases.
The $65 million that Hotspot Therapeutics Inc., of Boston, raised will help advance its lead programs to the clinic, including protein kinase C antagonists for Th2 and T-reg-driven autoimmune disease and S6 kinase antagonists for rare metabolic disease.